Related Experiment Videos
Preventing sudden death in coronary cardiomyopathy: implantable defibrillators lead the way
1Department of Cardiology, Cleveland Clinic Foundation, OH 44195, USA.
Insights
Electrophysiology testing-guided therapy, including defibrillator implantation, significantly lowers sudden cardiac death risk in high-risk coronary artery disease patients. All eligible patients should undergo testing and consider defibrillator implantation if indicated.
Area of Science:
- Cardiology
- Electrophysiology
- Clinical Trials
Background:
- Coronary artery disease (CAD) with reduced ejection fraction and ventricular arrhythmias poses a high risk of sudden cardiac death.
- Nonsustained ventricular tachycardia (NSVT) in this population requires risk stratification.
- Electrophysiology (EP) testing is a key tool for assessing arrhythmia inducibility.
Purpose of the Study:
- To evaluate the efficacy of EP testing-guided therapy in reducing mortality and cardiac arrest in high-risk CAD patients.
- To determine if implantable defibrillator (ICD) therapy is essential for risk reduction in this cohort.
Main Methods:
- The Multicenter Unsustained Tachycardia Trial (MUSTT) enrolled patients with CAD, LVEF ≤40%, and NSVT.
- Patients underwent EP testing to assess ventricular arrhythmia inducibility.
- Therapeutic strategies were guided by EP testing results, including ICD implantation.
Main Results:
- EP-guided therapy significantly reduced the risk of arrhythmic death and cardiac arrest.
- This benefit was primarily observed in patients who received an implantable defibrillator based on EP testing results.
- Patients with inducible ventricular arrhythmias on EP testing showed a marked benefit from ICD implantation.
Conclusions:
- EP testing is crucial for identifying patients with CAD, reduced LVEF, and NSVT who are at high risk for sudden cardiac death.
- Implantable defibrillator therapy guided by EP testing is highly effective in preventing arrhythmic events in this patient group.
- Routine EP testing and consideration of ICD implantation are recommended for all patients meeting MUSTT criteria.
Abstract:
The Multicenter Unsustained Tachycardia Trial (MUSTT) demonstrated that electrophysiologic testing (EP)-guided therapy significantly reduces arrhythmic death and cardiac arrest in patients with coronary artery disease, a left ventricular ejection fraction of 40% or less, nonsustained ventricular tachycardia, and inducible ventricular arrhythmia on EP testing-but only if the therapy includes an implantable defibrillator. All patients who meet the MUSTT inclusion criteria should undergo an EP test and if positive, should undergo defibrillator implantation.